Who are Levonorgestrel/Ethinyl Estradiol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ethinyl Estradiol + Cyproterone acetate, OCR, desogestrel/ethinyl estradiol, Ethinylestradiol / Dienogest, Nomegestrol Acetate / Estradiol, norelgestromin + ethinyl estradiol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levonorgestrel-ethinyl-estradiol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Levonorgestrel/Ethinyl Estradiol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Levonorgestrel/Ethinyl Estradiol (Levonorgestrel/Ethinyl Estradiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combined oral contraceptive. Area: Contraception / Gynecology.

marketed Combined oral contraceptive Progesterone receptor, estrogen receptor alpha and beta Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Levonorgestrel/Ethinyl Estradiol (Levonorgestrel/Ethinyl Estradiol) — Wyeth is now a wholly owned subsidiary of Pfizer. This combination oral contraceptive suppresses ovulation by inhibiting the luteinizing hormone surge through progestin and estrogen feedback on the hypothalamic-pituitary axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Levonorgestrel/Ethinyl Estradiol TARGET	Levonorgestrel/Ethinyl Estradiol	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor alpha and beta
Ethinyl Estradiol + Cyproterone acetate	Ethinyl Estradiol + Cyproterone acetate	Fundação Educacional Serra dos Órgãos	marketed	Combined oral contraceptive with anti-androgenic activity	Androgen receptor (cyproterone acetate); estrogen receptor (ethinyl estradiol); gonadotropin suppression
OCR	OCR	Hoffmann-La Roche	marketed	Combined oral contraceptive	Estrogen receptor and progesterone receptor
desogestrel/ethinyl estradiol	desogestrel/ethinyl estradiol	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Combined oral contraceptive	Progesterone receptor, estrogen receptor
Ethinylestradiol / Dienogest	Ethinylestradiol / Dienogest	University of Palermo	marketed	Combined oral contraceptive	Estrogen receptor, progesterone receptor
Nomegestrol Acetate / Estradiol	Nomegestrol Acetate / Estradiol	University of Palermo	marketed	Combined oral contraceptive	Progesterone receptor, Estrogen receptor
norelgestromin + ethinyl estradiol	norelgestromin + ethinyl estradiol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Combined oral contraceptive (progestin + estrogen)	Progesterone receptor, estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combined oral contraceptive class)

University of Palermo · 3 drugs in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
Organon and Co · 2 drugs in this class
HRA Pharma · 1 drug in this class
Hansoh BioMedical R&D Company · 1 drug in this class
Helsinki University Central Hospital · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
IVI Madrid · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levonorgestrel/Ethinyl Estradiol — Competitive Intelligence Brief. https://druglandscape.com/ci/levonorgestrel-ethinyl-estradiol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing